SCHEMBL3701908

SCHEMBL3701908

CC(C)(C)SC(=O)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.61
BCL9 O00512 1/20 0.54
CTNNB1 P35222 1/20 0.54
ALDH1A1 P00352 4/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KMT2A Q03164 3/20 0.49
PKM P14618 1/20 0.49
MGLL Q99685 2/20 0.48
MAPK1 P28482 3/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MYOC Q99972 1/20 0.47
NR1H4 Q96RI1 1/20 0.47
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.45
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4941164 0.79 ELANE (0.61) GAABCL9CTNNB1ALDH1A1SMN1; SMN2
SCHEMBL21528095 0.79 GAA (0.60) GAABCL9CTNNB1ALDH1A1SMN1; SMN2
SCHEMBL10309184 0.79 BCL9 (0.60) GAABCL9CTNNB1ALDH1A1SMN1; SMN2
SCHEMBL24311016 0.78 GAA (0.58) GAABCL9CTNNB1ALDH1A1SMN1; SMN2
SCHEMBL3310085 0.78 GAA (0.58) GAABCL9CTNNB1ALDH1A1SMN1; SMN2
SCHEMBL27355973 0.78 GAA (0.58) GAABCL9CTNNB1ALDH1A1SMN1; SMN2
SCHEMBL21410733 0.78 GAA (0.71) GAABCL9CTNNB1ALDH1A1SMN1; SMN2
4-Nitrophenyl Acetate SCHEMBL74985 0.77 GAA (0.66) GAABCL9CTNNB1ALDH1A1SMN1; SMN2
SCHEMBL21853704 0.77 GAA (0.57) GAABCL9CTNNB1ALDH1A1SMN1; SMN2
SCHEMBL1461897 0.77 ELANE (0.60) GAABCL9CTNNB1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2033654-B1 Process for resolving a mixture of alkyl ester enantiomers using an enzyme BRISTOL MYERS SQUIBB CO (US) 2012-05-16 EP disclosed
EP-2033654-B1 Process for resolving a mixture of alkyl ester enantiomers using an enzyme BRISTOL MYERS SQUIBB CO (US) 2012-05-16 EP disclosed
EP-2033654-A1 Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus Bristol-Myers Squibb Company (US) 2009-03-11 EP disclosed
EP-2033654-A1 Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus Bristol-Myers Squibb Company (US) 2009-03-11 EP disclosed
EP-1629000-B1 MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS BRISTOL MYERS SQUIBB CO (US) 2009-02-18 EP disclosed
EP-1629000-B1 MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS BRISTOL MYERS SQUIBB CO (US) 2009-02-18 EP disclosed
US-7173004-B2 Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 US disclosed
US-7173004-B2 Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 US disclosed
US-7173004-B2 Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 US disclosed
EP-1629000-A4 MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS BRISTOL MYERS SQUIBB CO (US) 2006-11-29 EP disclosed
US-20060257980-A1 Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus BRISTOL-MYERS SQUIBB COMPANY 2006-11-16 US disclosed
EP-1629000-A2 MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS Bristol-Myers Squibb Company (US) 2006-03-01 EP disclosed
WO-2004094452-A2 MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-04 WO disclosed